Skip to main content
    E

    Erasca Inc (ERAS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.11
    -0.55 (-3.51%)

    Market Cap: $5.50B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Erasca Inc (ERAS) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Erasca are CG Oncology, Inc. Common stock (CGON), Crispr Therapeutics AG (CRSP) and Travere Therapeutics (TVTX). By market cap, Erasca ranks 3rd of the 13 companies on this page; Abivax SA American Depositary Shares (ABVX) is the largest at $7.67B.

    Peer Comparison

    ERAS's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Erasca (ERAS)$5.50BN/AN/A0.0%N/A0.0%0.00%
    CG Oncology, Inc. Common stock (CGON)$6.65BN/AN/A0.0%-21.1%-3.7%0.00%
    Crispr Therapeutics AG (CRSP)$4.10BN/A155.2x0.0%-20.3%1325.0%0.00%
    Travere Therapeutics Inc (TVTX)$4.86BN/A7.2x-18.7%-23.1%36.2%0.00%
    Abivax SA American Depositary Shares (ABVX)$7.67BN/AN/A0.0%-159.6%-6.8%0.00%
    Enliven Therapeutics Inc. (ELVN)$3.59BN/AN/A0.0%N/A0.0%0.00%
    Tango Therapeutics Inc (TNGX)$4.32BN/AN/A0.0%N/A-100.0%0.00%
    Edgewise Therapeutics Inc (EWTX)$5.03BN/AN/A0.0%N/A0.0%0.00%
    Arcus Biosciences Inc (RCUS)$2.51BN/A21.5x0.0%-75.9%-65.4%0.00%
    Iovance Biotherapeutics Inc (IOVA)$3.59BN/A9.1x-58.2%N/A80.1%0.00%
    Arcutis Biotherapeutics Inc (ARQT)$3.57B129.3x7.0x5.9%7.8%45.1%0.00%
    Cogent Biosciences Inc (COGT)$4.97BN/AN/A0.0%-43.4%-100.0%0.00%
    Xencor Inc (XNCR)$2.78BN/A13.5x-58.8%-17.3%454.9%0.00%
    Peer median$4.21B129.3x11.3x0.0%-22.1%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Erasca, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    CG Oncology, Inc. Common stock (CGON)
    CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070...
    CGON competitors
    Crispr Therapeutics AG (CRSP)
    CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases.
    CRSP competitors
    Travere Therapeutics Inc (TVTX)
    Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification...
    TVTX competitors
    Abivax SA American Depositary Shares (ABVX)
    Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections.
    ABVX competitors
    Enliven Therapeutics Inc. (ELVN)
    Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare...
    ELVN competitors
    Tango Therapeutics Inc (TNGX)
    Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation...
    TNGX competitors
    Edgewise Therapeutics Inc (EWTX)
    Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases.
    EWTX competitors
    Arcus Biosciences Inc (RCUS)
    Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States.
    RCUS competitors
    Iovance Biotherapeutics Inc (IOVA)
    Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness...
    IOVA competitors
    Arcutis Biotherapeutics Inc (ARQT)
    Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
    ARQT competitors
    Cogent Biosciences Inc (COGT)
    Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases.
    COGT competitors
    Xencor Inc (XNCR)
    Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed...
    XNCR competitors

    Frequently Asked Questions About ERAS

    Who are Erasca's main competitors?

    The companies most similar to Erasca include CG Oncology, Inc. Common stock (CGON), Crispr Therapeutics AG (CRSP), Travere Therapeutics (TVTX), Abivax SA American Depositary Shares (ABVX) and Enliven Therapeutics (ELVN), listed from the closest match.

    Who is Erasca's biggest competitor?

    Abivax SA American Depositary Shares (ABVX) is the largest of the similar companies at $7.67B; CG Oncology, Inc. Common stock (CGON) is the closest match by business profile, size, sector and industry.

    How does ERAS stock compare with its competitors?

    ERAS' net margin is 0.0% against a peer median of 0.0%.

    Which of Erasca's competitors pays a higher dividend?

    Erasca pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Erasca bigger than its competitors?

    No. Erasca is 3rd by market cap among the 13 companies on this page; the largest is Abivax SA American Depositary Shares (ABVX) at $7.67B.